摘要
目的:分析上海市同济医院消化系统用药近况和发展趋势,为临床合理用药提供依据。方法:采用限定日剂量(DDD)为指标的方法,对我院2016年1月—2017年6月消化系统用药的品种销售金额、用药频度(DDDs)和限定日费用(DDC)等数据进行统计和分析。结果:经过分析数据排序显示,用药金额排名前5位的分别是兰索拉唑胶囊、雷贝拉唑钠肠溶胶囊、奥美拉唑镁肠溶片、莫沙必利片和瑞巴派特片;用药频度(DDDs)排名前5位的分别是兰索拉唑、瑞巴派特、奥美拉唑、莫沙必利和雷贝拉唑;日均费用(DDC)排名前5位的分别是枸橼酸雷尼替丁、匹维溴铵、雷贝拉唑、奥美拉唑和兰索拉唑。结论:我院的门诊消化系统用药较为合理。质子泵抑制剂(PPI)已成为临床占据绝对优势的一线用药。但是每种PPI在药代动力学、药理作用和临床应用等方面还是存在差异的,可根据药物各自的特点合理选用药物。
Objective： To analyze medication status in digestive system of our hospital and its development trend so as to provide a reference for clinical rational drug use. Methods： The data of the sales of drug varieties, DDDs and DDC from the medication of digestive system from January 2016 to June 2017 in our hospital were statistically analyzed by taking DDD as index. Results： The top fve drugs ranked in sales were lansoprazole capsule, rabeprazole enteric-coated capsule, omeprazole enteric-coated tablets, mosapride and rebamipide tablets. The top five ranked in DDDs were lansoprazole, rebamipide, omeprazole, mosapride and rabeprazole. The top fve ranked in DDC were ranitidine citrate, pinaverium bromide, lansoprazole, omeprazole and rabeprazole. Conclusion： The drug use in digestive system is reasonable in the outpatient of our hospital and proton pump inhibitors （PPI） become the frst-line medication with clinically absolute advantage. However, there are diferences in the pharmacokinetics, pharmacological action and clinical application of each PPI, so they can be reasonably selected based on their respective characteristics.
出处
《上海医药》
CAS
2018年第1期57-60,共4页
Shanghai Medical & Pharmaceutical Journal
